Stockscreener 앱 받기
31.67
1.25%
-0.40
시간 외 거래:
31.67
전일 마감가:
$32.07
열려 있는:
$32.21
하루 거래량:
810.26K
Relative Volume:
0.90
시가총액:
$2.78B
수익:
$214.83M
순이익/손실:
$-160.74M
주가수익비율:
-17.07
EPS:
-1.8553
순현금흐름:
$-105.39M
1주 성능:
+2.43%
1개월 성능:
-8.99%
6개월 성능:
+28.17%
1년 성능:
+51.89%
1일 변동 폭
$31.58
$32.95
1주일 범위
$30.81
$33.31
52주 변동 폭
$13.45
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
명칭
Ideaya Biosciences Inc
전화
650-443-6209
주소
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
31.67 | 2.82B | 214.83M | -160.74M | -105.39M | -1.8553 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-09-04 | 개시 | Barclays | Overweight |
| 2025-09-04 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-07-22 | 개시 | TD Cowen | Buy |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-06-26 | 개시 | Wells Fargo | Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-11-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2024-03-08 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | SVB Securities | Outperform |
| 2023-05-24 | 개시 | Goldman | Buy |
| 2023-04-24 | 업그레이드 | Stifel | Hold → Buy |
| 2023-03-23 | 개시 | Berenberg | Buy |
| 2023-02-28 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-28 | 개시 | CapitalOne | Overweight |
| 2022-10-27 | 개시 | Citigroup | Buy |
| 2022-08-15 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-10 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-03-11 | 개시 | Guggenheim | Buy |
| 2020-10-07 | 개시 | Wedbush | Outperform |
| 2020-09-01 | 개시 | Northland Capital | Outperform |
| 2020-07-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-06 | 개시 | H.C. Wainwright | Buy |
| 2020-03-13 | 개시 | ROTH Capital | Buy |
| 2019-10-17 | 개시 | Oppenheimer | Outperform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-06-17 | 개시 | Citigroup | Buy |
| 2019-06-17 | 개시 | JP Morgan | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
모두보기
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
(IDYA) Risk Channels and Responsive Allocation - Stock Traders Daily
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC - The AI Journal
Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of Ide034, A Potential First-In-Class B7h3/Ptk7 Bispecific Top1 Adc - TradingView
Published on: 2026-02-25 12:19:59 - baoquankhu1.vn
Published on: 2026-02-24 09:21:42 - baoquankhu1.vn
IDEAYA Biosciences appoints Theodora Ross as development chief By Investing.com - Investing.com South Africa
IDEAYA Biosciences Teases Late-March Phase III Darovasertib Readout, ADC Updates, New KAT6/7 Phase I Launch - Yahoo Finance
IDYA: Darovasertib's phase 3 PFS readout is imminent, with accelerated approval filing expected this year - TradingView
IDEAYA Biosciences Teases End-of-March Data for Darovasertib Combo at Citi Oncology Summit - Yahoo Finance
Can IDEAYA Biosciences Inc reach all time highs this yearWeekly Stock Analysis & High Accuracy Trade Signal Alerts - baoquankhu1.vn
IDEAYA Biosciences appoints Theodora Ross as development chief - Investing.com
Theodora Ross Joins Ideaya, Leaving Impact on AbbVie (ABBV) - GuruFocus
Ideaya Biosciences Announces Appointment Of Dr. Theodora (Theo) Ross, M.D., Ph.D., As Chief Development Officer - TradingView
AbbVie cancer R&D leader takes charge of IDEAYA’s drug pipeline - Stock Titan
Is IDEAYA Biosciences Inc. forming a breakout patternWeekly Risk Summary & Consistent Growth Equity Picks - mfd.ru
What’s the analyst consensus on IDEAYA Biosciences Inc.Earnings Risk Summary & Weekly Stock Breakout Alerts - mfd.ru
Cantor Fitzgerald reiterates Ideaya Biosciences stock Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Ideaya Biosciences stock Overweight rating - Investing.com
Wedbush Adjusts Price Target on IDEAYA Biosciences to $52 From $49, Maintains Outperform Rating - marketscreener.com
Cantor Fitzgerald Maintains Overweight on IDEAYA (IDYA) Feb 18, 2026 - Meyka
IDEAYA Biosciences, Inc. SEC 10-K Report - TradingView
Published on: 2026-02-17 23:06:22 - mfd.ru
Wedbush Adjusts IDEAYA Biosciences Price Target to $52 From $49, Maintains Outperform Rating - marketscreener.com
Ideaya Biosciences earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - Finviz
Ideaya Biosciences Q4 Net Loss Narrows as Revenue Rises - marketscreener.com
Earnings Flash (IDYA) IDEAYA Biosciences Posts Q4 Net Loss $0.94 a Share, vs. FactSet Est of $1.05 Loss - marketscreener.com
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q4 Revenue $10.9M, vs. FactSet Est of $6.3M - marketscreener.com
IDEAYA Biosciences Q4 Loss Declines - Nasdaq
What is IDEAYA Biosciences Inc. s P E ratio telling usJuly 2025 Trends & Verified Swing Trading Watchlists - mfd.ru
(IDYA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Is IDEAYA Biosciences Inc. benefiting from innovation trendsJuly 2025 Price Swings & Weekly Stock Breakout Alerts - mfd.ru
What is IDEAYA Biosciences Inc.’s book value per share2025 EndofYear Setup & Smart Swing Trading Techniques - mfd.ru
IDEAYA Biosciences, Inc. $IDYA Shares Acquired by Candriam S.C.A. - MarketBeat
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: A 54% Potential Upside in the Precision Medicine Oncology Space - DirectorsTalk Interviews
Citizens reiterates Market Outperform rating on Ideaya Biosciences stock By Investing.com - Investing.com Canada
IDEAYA Biosciences (IDYA): Unpacking The 46.63% Potential Upside In Precision Oncology - DirectorsTalk Interviews
IDEAYA Biosciences, Inc. $IDYA Shares Acquired by New York State Common Retirement Fund - MarketBeat
Liquidity Mapping Around (IDYA) Price Events - Stock Traders Daily
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events - MEXC
Has The Market Overreacted To Recent Weakness In IDEAYA Biosciences (IDYA) Shares? - Yahoo Finance
AlphaQuest LLC Has $1.12 Million Stock Position in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events – Company Announcement - Financial Times
Institution Moves: Is IDEAYA Biosciences Inc benefiting from innovation trends2025 Support & Resistance & Safe Capital Investment Plans - baoquankhu1.vn
A Look At IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Pullback - Yahoo Finance
Knights of Columbus Asset Advisors LLC Invests $934,000 in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
IDEAYA Grants 44,200 Stock Options to New Employee - intellectia.ai
Ideaya Biosciences announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
New IDEAYA hire receives 44,200 stock options in Nasdaq inducement grant - stocktitan.net
Forecast Cut: Will IDEAYA Biosciences Inc benefit from geopolitical trendsWatch List & Consistent Income Trade Recommendations - baoquankhu1.vn
Ideaya Biosciences Inc (IDYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.52%
1.68%
자본화:
|
볼륨(24시간):